I-Mab (IMAB) shares were up more than 16% in recent Monday trading after the company said it will focus on advancing givastomig as its lead program targeting first-line metastatic gastric cancers, with further potential in other solid tumors.
A dose escalation study of givastomig with nivolumab plus chemotherapy has been completed, and the data are expected in the early second half of 2025, I-Mab said.
The biotech company said a dose expansion study involving 40 patients is underway, with data expected in early 2026.
I-Mab said its cash position would be able to fund the givastomig phase 1b study through dose expansion data readouts and further development plans into 2027.
Price: 1.07, Change: +0.16, Percent Change: +16.94
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.